Global Modulators of the Genital System and Sex Hormones Sales Share by Country (Million US Dollars PPP)

In 2023, Canada experienced a year-on-year decline of -2.73% in sales share of modulators of the genital system and sex hormones, bringing its revenue down to 18.81 million US dollars PPP. Conversely, Germany saw a modest increase of 1.27% to 17.12 million, and Chile exhibited robust growth of 4.24%, reaching 12.77 million. South Korea experienced the highest increase of 6.63%, now at 10.85 million, while Australia grew by 4.51% to 7.26 million. The Czech Republic had a slight growth of 0.38%, hitting 5.49 million, and Spain saw a minor decline of -0.84%, lowering its share to 5.04 million. Croatia increased by 0.7% to 4.75 million, and Sweden by 2.4% to 3.68 million. Portugal also exhibited growth of 1.67%, reaching 3.64 million.

Furthermore, Greece had a slight decline of -0.3% to 2.27 million, while Norway showed a small increase of 0.94% to 1.92 million. Finland declined by -2.06% to 1.92 million, and Hungary decreased by -1.06% to 1.21 million. Slovakia saw a minor decline of -0.17% to 1.09 million, and Austria slightly dipped by -0.13% to 0.49 million. Notably, New Zealand exhibited significant growth of 9.78%, achieving 0.37 million. Slovenia declined by -3.09% to 0.33 million, while Estonia increased by 0.8% to 0.32 million. Costa Rica saw a growth of 2.29%, reaching 0.26 million, and Iceland increased by 4.64% to 0.22 million. Luxembourg experienced a growth of 2.09%, now at 0.16 million.

Future trends to watch include the continued robust growth in emerging markets like South Korea and New Zealand, driven by increasing healthcare expenditure and greater acceptance of hormonal therapies. Additionally, the modest gains in established markets such as Germany and Portugal suggest a stable yet competitive landscape. Attention should also be given to markets showing declines, like Canada and Finland, which may need strategic interventions to revive growth.